DFTX Insider Trading Activity and SEC Form 4 Filings
DFTX insider trading summary
Over the past 12 months, insiders at Definium Therapeutics, Inc. (DFTX) reported 6 sales worth $3.0M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $3.0M.
Latest DFTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Brandi Roberts | Chief Financial Officer | Sell | $123K (3,377 @ $36.57) |
| Sep 25, 2026 | Mark Sullivan | Chief Legal Officer | Sell | $514K (14,051 @ $36.57) |
| Sep 25, 2026 | Matthew T. Wiley | Chief Commercial Officer | Sell | $113K (3,097 @ $36.57) |
| Sep 25, 2026 | Robert Barrow | Chief Executive Officer | Sell | $1.2M (31,550 @ $36.57) |
| Sep 25, 2026 | Daniel Karlin | Chief Medical Officer | Sell | $397K (10,853 @ $36.57) |
| Sep 3, 2026 | Robert Barrow | Chief Executive Officer | Sell | $722K (19,023 @ $37.94) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.